Raymond L Jones

US Patent:

20020041880, Apr 11, 2002

Filed:

Jun 29, 2001

Appl. No.:

09/896251

Inventors:

Deborah DeFeo-Jones - Lansdale PA, US
David Heimbrook - Coopersburg PA, US
Raymond Jones - Lansdale PA, US

International Classification:

A61K039/00
A61K038/14
A61K038/08

US Classification:

424/185100, 514/017000, 514/008000

Abstract:

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of angiogenesis. The invention also relates to methods of preparing such compositions.

US Patent:

20020173451, Nov 21, 2002

Filed:

Oct 2, 2001

Appl. No.:

09/969244

Inventors:

Raymond Jones - Lansdale PA, US
Deborah DeFeo-Jones - Lansdale PA, US
David Heimbrook - Coopersburg PA, US
Patricia Rhymer - Martinsville NJ, US
Pamela Wasserbly - Doylestown PA, US

International Classification:

A61K038/16
C07K009/00
A61N005/00

US Classification:

514/008000, 600/001000, 530/322000, 530/395000

Abstract:

The present invention relates to methods of treating cancer using a combination of a PSA conjugate and radiation therapy. The methods of this invention comprise administering to a mammal in need amounts of at least one PSA conjugate, in combination with radiation therapy, either sequentially or concomitantly.

US Patent:

20030133927, Jul 17, 2003

Filed:

Oct 10, 2002

Appl. No.:

10/268552

Inventors:

Deborah DeFeo-Jones - Lansdale PA, US
Raymond Jones - Lansdale PA, US

International Classification:

A61K038/48
C12N009/99

US Classification:

424/094630, 435/184000

Abstract:

Chemical conjugates which comprise an oligopeptide covalently bonded, either directly or through a chemical linker, to a peptide or small molecule that binds to an anti-apoptotic Bcl-2 family protein, inhibits the expression of the Bcl-2 family protein, or inhibits the function of the Bcl-2 family protein. Such a peptide or small molecule that binds to an anti-apoptotic Bcl-2 family protein, inhibits the expression of the Bcl-2 family protein, or inhibits the function of the Bcl-2 family protein may be conveniently referred to as a therapeutic agent. The oligopeptides are chosen from oligomers that are selectively recognized by the free prostate specific antigen (PSA) and are capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen.

US Patent:

20030215456, Nov 20, 2003

Filed:

Oct 2, 2001

Appl. No.:

09/969322

Inventors:

Raymond Jones - Lansdale PA, US
Deborah DeFeo-Jones - Lansdale PA, US
David Heimbrook - Coopersburg PA, US
Patricia Rhymer - Martinsville NJ, US
Pamela Wasserbly - Doylestown PA, US

International Classification:

A61K039/00
A61K038/14

US Classification:

424/185100, 424/277100, 514/008000

Abstract:

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a tachykinin receptor antagonist, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a tachykinin receptor antagonist. The invention also relates to methods of preparing such compositions.

US Patent:

59983620, Dec 7, 1999

Filed:

Sep 9, 1997

Appl. No.:

8/926412

Inventors:

Dong-Mei Feng - Blue Bell PA
Victor M. Garsky - Blue Bell PA
Raymond E. Jones - Lansdale PA
Jenny M. Wai - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3814
C07K 400

US Classification:

514 2

Abstract:

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA), hydrophilic oligopeptide blocking groups and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).

US Patent:

61438642, Nov 7, 2000

Filed:

Jun 6, 1995

Appl. No.:

8/468161

Inventors:

Deborah DeFeo-Jones - Lansdale PA
Dong-Mei Feng - Harleysville PA
Victor M. Garsky - Blue Bell PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3814
C07K 900

US Classification:

530322

Abstract:

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

US Patent:

58666796, Feb 2, 1999

Filed:

Oct 6, 1995

Appl. No.:

8/540412

Inventors:

Deborah DeFeo-Jones - Lansdale PA
Victor M. Garsky - Blue Bell PA
Dong-Mei Feng - Harleysville PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 509
A61K 3800

US Classification:

530322

Abstract:

Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.

US Patent:

61774049, Jan 23, 2001

Filed:

Aug 3, 1998

Appl. No.:

9/051759

Inventors:

Deborah DeFeo-Jones - Lansdale PA
Raymond E. Jones - Lansdale PA
Allen I. Oliff - Gwynedd Valley PA
Edward M. Scolnick - Wynnewood PA
Victor M. Garsky - Blue Bell PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3816

US Classification:

514 8

Abstract:

Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent are described. Methods of treating benign prostate hypertrophy are also disclosed.